111 related articles for article (PubMed ID: 21861595)
1. Flare up of symptoms after discontinuation of sunitinib in patient with lung cancer.
Guo W; Liu X; Gao H
Acta Oncol; 2011 Oct; 50(7):1133-5. PubMed ID: 21861595
[No Abstract] [Full Text] [Related]
2. Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene.
Wu H; Shih JY; Yang JC
J Thorac Oncol; 2015 Sep; 10(9):e95-e96. PubMed ID: 26291023
[No Abstract] [Full Text] [Related]
3. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).
Ready NE; Pang HH; Gu L; Otterson GA; Thomas SP; Miller AA; Baggstrom M; Masters GA; Graziano SL; Crawford J; Bogart J; Vokes EE
J Clin Oncol; 2015 May; 33(15):1660-5. PubMed ID: 25732163
[TBL] [Abstract][Full Text] [Related]
5. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
Shi HZ; Tian J; Chen X; Wang D; Li CL
Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518
[TBL] [Abstract][Full Text] [Related]
6. The evaluation of efficacy and safety of sunitinib on EGFR-TKI pretreated advanced non-small cell lung cancer patients in China.
Liu YR; Zhu W; Zhang JL; Huang JQ; Zhao YZ; Zhang W; Han BH; Yao YH; Jiang LY; Li SQ
Clin Respir J; 2014 Apr; 8(2):206-12. PubMed ID: 24118906
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant sunitinib following chemoradiotherapy and surgery for locally advanced esophageal cancer: a phase II trial.
Horgan AM; Darling G; Wong R; Guindi M; Liu G; Jonker DJ; Lister J; Xu W; MacKay HM; Dinniwell R; Kim J; Pierre A; Shargall Y; Asmis TR; Agboola O; Seely AJ; Ringash J; Wells J; Marginean EC; Haider M; Knox JJ
Dis Esophagus; 2016 Nov; 29(8):1152-1158. PubMed ID: 26663741
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib: the next advance in small-cell lung cancer?
Leighl NB
J Clin Oncol; 2015 May; 33(15):1637-9. PubMed ID: 25870089
[No Abstract] [Full Text] [Related]
9. Refractory cutaneous angiosarcoma successfully treated with sunitinib.
Lu HJ; Chen PC; Yen CC; Hsiao FC; Tzeng CH; Ma H; Shiau CY; Chao TC
Br J Dermatol; 2013 Jul; 169(1):204-6. PubMed ID: 23383874
[No Abstract] [Full Text] [Related]
10. Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.
Gervais R; Hainsworth JD; Blais N; Besse B; Laskin J; Hamm JT; Lipton A; Albain KS; Masters GA; Natale RB; Selaru P; Kim ST; Chao RC; Page RD
Lung Cancer; 2011 Dec; 74(3):474-80. PubMed ID: 21680048
[TBL] [Abstract][Full Text] [Related]
11. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061).
Abdelraouf F; Smit E; Hasan B; Menis J; Popat S; van Meerbeeck JP; Surmont VF; Baas P; O'Brien M
Eur J Cancer; 2016 Feb; 54():35-39. PubMed ID: 26716400
[TBL] [Abstract][Full Text] [Related]
13. Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma.
Kahl C; Hilgendorf I; Freund M; Casper J
Onkologie; 2008 Sep; 31(8-9):485. PubMed ID: 18787358
[No Abstract] [Full Text] [Related]
14. Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases.
Novello S; Camps C; Grossi F; Mazieres J; Abrey L; Vernejoux JM; Thall A; Patyna S; Usari T; Wang Z; Chao RC; Scagliotti G
J Thorac Oncol; 2011 Jul; 6(7):1260-6. PubMed ID: 21610524
[TBL] [Abstract][Full Text] [Related]
15. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
16. Kidney cancer: Power couple: reovirus meets sunitinib.
Thoma C
Nat Rev Urol; 2016 Aug; 13(8):436. PubMed ID: 27296650
[No Abstract] [Full Text] [Related]
17. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
Kim JH; Park I; Lee JL
Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
[TBL] [Abstract][Full Text] [Related]
18. Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer.
Harshman L; Srinivas S
Onkologie; 2008 Sep; 31(8-9):432-3. PubMed ID: 18787349
[No Abstract] [Full Text] [Related]
19. An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
Cardoso F; Canon JL; Amadori D; Aldrighetti D; Machiels JP; Bouko Y; Verkh L; Usari T; Kern KA; Giorgetti C; Dirix L
Breast; 2012 Dec; 21(6):716-23. PubMed ID: 23022045
[TBL] [Abstract][Full Text] [Related]
20. Clinical benefit of sunitinib in gastrointestinal stromal tumors with different exon 11 mutation genotypes.
Dong Z; Gao J; Gong J; Li J; Li Y; Shen L; Li J
Future Oncol; 2017 Oct; 13(23):2035-2043. PubMed ID: 28685593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]